Trk receptor

May 15, 2019

Bayer presents new analyses for Vitrakvi® (larotrectinib) in adult and pediatric patients with TRK fusion cancer with solid tumors, and new data in primary central nervous system tumors and brain metastases

Dec 17, 2018

Pyramid Biosciences Announces Exclusive Global License of AstraZeneca TRK Program for Dermatology and Inflammatory Diseases

Nov 27, 2018

Roche launches first IVD pan-TRK immunohistochemistry assay

Oct 22, 2018

SeraCare Announces Launch of Expanded NTRK Reference Material Panel

Oct 21, 2018

Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients Across Ages and Tumor Types

May 29, 2018

FDA Accepts Larotrectinib New Drug Application and Grants Priority Review

Mar 26, 2018

Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer

Feb 21, 2018

Bayer Announces Publication of Larotrectinib Data in The New England Journal of Medicine

Dec 20, 2017

Bayer Announces that Loxo Oncology, Inc., Initiates Rolling NDA Submission for Larotrectinib for the Treatment of TRK Fusion Cancers

Dec 04, 2017

Updated larotrectinib pediatric Phase I clinical trial data demonstrates response in TRK fusion cancers